Copyright
©2007 Baishideng Publishing Group Co.
World J Gastroenterol. Jul 28, 2007; 13(28): 3799-3805
Published online Jul 28, 2007. doi: 10.3748/wjg.v13.i28.3799
Published online Jul 28, 2007. doi: 10.3748/wjg.v13.i28.3799
Chemotherapy Regimen | Drugs | Route | Dosage | Cycle length and number |
Mayo Regimen[58] | 5-FU/LV | iv | 5-FU, 425 mg/m2 per day d 1-5 | 28 d |
LV 20 mg/m2 per day d 1-5 | 6 cycles | |||
Roswell Park [59] | 5-FU/LV | iv | 5-FU 500 mg/m2 per day weekly × 6 | 8 wk |
LV 500 mg/m2 per day weekly × 6 | 4 cycles | |||
Xeloda [24] | Capecitabine | oral | 1250 mg/m2 | 21d |
BD × 14 d | 8 cycles | |||
FOLFOX 4 [31] | 5-FU/LV | iv | Oxaliplatin 85 mg/m2 d 1 | 14 d |
Oxaliplatin | LV 200 mg/m2 per d d 1-2 | 12 cycles | ||
5-FU 400 mg/m2 per day d 1-2 | ||||
5-FU, 600 mg/m2 per d CVI over 22 h, d 1-2 | ||||
FLOX [32] | 5-FU/LV | iv | Oxaliplatin 85 mg/m2 wk 1, 3, 5 | 8 wk |
Oxaliplatin | LV 500 mg/m2 wk 1-6 | 3 cycles | ||
5-FU 500 mg/m2 wk 1-6 |
- Citation: Kosmider S, Lipton L. Adjuvant therapies for colorectal cancer. World J Gastroenterol 2007; 13(28): 3799-3805
- URL: https://www.wjgnet.com/1007-9327/full/v13/i28/3799.htm
- DOI: https://dx.doi.org/10.3748/wjg.v13.i28.3799